Last reviewed · How we verify
INCS
At a glance
| Generic name | INCS |
|---|---|
| Sponsor | University of Aarhus |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) (PHASE3)
- A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) (PHASE3)
- Viral and Epigenetic Influences in CRSwNP
- Effect of Pleuran on the Clinical Course of Patients With Chronic Rhinosinusitis (NA)
- Allergic Rhinitis Improvement Through Strategic Education: The ARISE Trial (NA)
- Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (PHASE3)
- A Prospective, Randomized, Controlled Study Comparing the Efficacy of Intranasal Corticosteroids (INCS) Combined With Intranasal Antihistamines (INAH) and INCS Combined With Oral Antihistamines (OAH) in the Treatment of Moderate to Severe Allergic Rhinitis Symptoms (PHASE4)
- As Needed Versus Regular Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- INCS CI brief — competitive landscape report
- INCS updates RSS · CI watch RSS
- University of Aarhus portfolio CI